Results of a study on lenacapavir and two broadly neutralizing antibodies were presen
At the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, results were presented from a Phase II study examining the efficacy of a combination of lenacapavir (TN Sunlenca) and twoRead More